期刊
MOVEMENT DISORDERS
卷 24, 期 3, 页码 407-413出版社
WILEY-LISS
DOI: 10.1002/mds.22368
关键词
blepharospasm; botulinum toxin; Jankovic Rating Scale; Blepharospasm Disability Index
The objective was to analyze the metric properties of the Jankovic Raring Scale (JRS) and a self-rating patient response Outcome scale, the Blepharospasm Disability Index (BSDI (c)), in blepharospasm patients. Data from a randomized, double-blind, active-control clinical trial in 300 patients with blepharospasm treated with either botulinum toxin type A (Botox (R)) or NT201 (Xeomin (R)) were used to evaluate the metric properties OF the JRS and the BSDI compared with the Patient Evaluation of Global Response (PEGR) and Global Assessment Scale (GAS). The internal consistency of the BSDI was high, Cronbach's Alpha = 0.88, and the retest reliability of the E;SDI single items was adequate, Spear-man's rank coefficient = 0.453 < r < 0.595. The correlation between JRS sum score and BSDI weighted mean score was r = 0.487 (baseline) and r = 0.737 (control visit), respectively. Using the GAS and PEGR, the results suggest that a change Of 2 points in the JRS and of 0.7 points in the BSDI are clinically meaningful. JRS and BSDI are objective indicators of clinical efficacy as suggested by their good Validity when compared with physicians' and patients' rating scales. Both, JRS and BSDI, call be used to reliably assess blepharospasm in treatment trials. (C) 2008 Movement Disorder Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据